Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $85.7 million versus the consensus estimate of $90.36 million.

GUIDANCE:

2021 revenue guidance $375 - 405 million

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.